Ninety-day Local Tolerability and Toxicity Study of ND0612, a Novel Formulation of Levodopa/Carbidopa, Administered by Subcutaneous Continuous Infusion in Minipigs

作者：Ramot Yuval; Nyska Abraham^*; Maronpot Robert R; Shaltiel Karyo Ronit; Tsarfati Yonit; Manno Rosa Anna; Sacco Giuseppe; Yacoby Zeevi Oron

来源：Toxicologic Pathology, 2017, 45(6): 764-773.

DOI：10.1177/0192623317729891

• levodopa
• carbidopa
• Parkinson's disease
• infusion site reaction
• preclinical toxicity
• minipigs
• toxicologic pathology
• safety
• tolerability
• 3Rs

A 90-day study in Gottingen minipigs was conducted to test the local tolerability and systemic toxicity of ND0612, a novel aqueous solution of carbidopa (CD)/levodopa (LD) intended for the treatment of Parkinson's disease by continuous subcutaneous administration using a discrete infusion pump. To evaluate tissue site reactions, we used a unique study design involving multiple infusion sites to evaluate the effect of dose per site (270/63, 360/45, and 360/84 mg LD/CD), volume of infusion per site (4.5 and 6 ml per site), formulation concentration (60/14 and 60/7.5 mg/ml LD/CD), daily rate of infusion per site (240 l/hr for16 hr and 80 l/hr for 8 hr, 320 l/hr for 16 hr and 100 l/hr for 8 hr, or 750 l/hr for 8 hr), frequency (once every 5, 10, 15, or 20 days), and number of infusions (4, 6, or 9) to the same infusion site. No systemic adverse effects were observed. Histopathological changes at infusion sites started with localized minimal necrosis and acute inflammation that progressed to subacute and chronic inflammatory and reparative changes with evidence of progressive recovery following the final infusion. None of the infusion site effects were judged to be adverse, and clinical exposures to ND0612 are not expected to result in adverse responses.

• 出版日期2017-8